Allison Gatlin's profile photo

Allison Gatlin

California

Tech Reporter and New America Editor at Investor's Business Daily

Biopharma and medtech reporter for Investor's Business Daily, @IBDinvestors. @Cronkite_ASU alumna, taco connoisseur and twin mom. She/her.

Featured in: Favicon investors.com Favicon usatoday.com Favicon yahoo.com (+3) Favicon chicagotribune.com Favicon csmonitor.com Favicon flipboard.com Favicon nasdaq.com Favicon orlandosentinel.com Favicon dailypress.com Favicon bakersfield.com

Articles

  • Johnson & Johnson Stock Skids Despite First-Quarter Beat, Sales Guidance Hike

    6 days ago | investors.com | Allison Gatlin

    Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning.

  • Bristol Myers Squibb Skids On Heart Drug Failure, Tugging Cytokinetics Lower

    1 week ago | investors.com | Allison Gatlin

    Bristol Myers Squibb (BMY) stock skidded late Monday — tugging shares of rival Cytokinetics (CYTK) lower — after Bristol's drug, Camzyos, failed in a final-phase study of patients with a devastating heart disease. The company tested Camzyos in patients with nonobstructive hypertrophic cardiomyopathy, or nHCM. In this condition, the heart muscle thickens, making it harder to pump blood.

  • Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury

    1 week ago | investors.com | Allison Gatlin

    Pfizer (PFE) said Monday it's scrapping development of its daily weight-loss pill, danuglipron, after a patient experienced a potential drug-induced liver injury. The injury has since resolved, Pfizer said in a news release. The overall frequency of elevations in liver enzymes across 1,400 patients has been in line with approved drugs in the same class.

  • Argenx Stock Surges After Winning Approval For At-Home Vyvgart Hytrulo

    1 week ago | investors.com | Allison Gatlin

    Argenx (ARGX) stock jumped Friday after the Food and Drug Administration cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The decision updates the label for Vyvgart Hytrulo, an under-the-skin-treatment for neuromuscular condition generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, or CIDP. Patients can now use a prefilled syringe to treat themselves at home.

  • Trump's Tariffs Whiplash Rattles S&P, Dow Jones Drug Names

    1 week ago | investors.com | Allison Gatlin

    Big pharmaceutical names took another bath Thursday after the Trump administration said the 90-day delay for reciprocal tariffs doesn't apply to sector-specific tariffs. This means tariffs could be coming for drug imports — and soon.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
7K
Tweets
10K
DMs Open
Yes
Allison Gatlin
Allison Gatlin @IBD_AGatlin
3 Oct 22

Two of the best-rated biotech stocks are also among the worst performers today. Here's why. $APLS $BLTE https://t.co/riqaFbn0gO

Allison Gatlin
Allison Gatlin @IBD_AGatlin
23 Aug 22

When you email a PR person ENDLESSLY about a specific topic... only to see him quoted in another publication about said topic (after ghosting you for a month). Yes, this is a subtweet. Yes, I'm bitter.

Allison Gatlin
Allison Gatlin @IBD_AGatlin
22 Aug 22

Highly rated $SGFY and $PRVA surged today on news $AMZN, $UNH, $CVS and $OPCH. https://t.co/caicsaopHy